THERANOVA-LIM : améliorer l’accès à l’information sur les traitements oraux pour les patients et les pharmaciens

Résumé fourni par la source

OBJECTIVES: To evaluate patient and pharmacist satisfaction with two information systems using QR codes to access information about oral cancer treatments. METHODS: THERANOVA-LIM (NCT04931329) was a prospective, descriptive, single-centre study of cancer patients receiving oral treatment. Patients were divided into two groups: one group using the information card and the other using the standard prescription with QR code. Patient satisfaction was assessed at 3 months using questionnaires. RESULTS: In all, 128 patients were included: 55 received a 'drug information card' and 73 a 'prescription with QR code'. The median age was 69 (37-90). The three most common cancers were breast (37.5%), prostate (14.1%) and brain (10.9%). The vast majority of patients had metastatic cancer (90%). The three most prescribed drugs were capecitabine (21.1%), ribociclib (11.7%) and temozolomide (11.7%). Patients presented the QR codes during medical consultations (25.0%), pharmacy visits (100%) and during home visits by nurses (25.0%). Both patients and professionals were satisfied with these new systems. Pharmacists felt that the prescription with a QR code was more useful for their daily practice in the pharmacy (P=0.02). CONCLUSIONS: QR code systems proved effective in providing information to patients and healthcare professionals. The QR code prescription appeared to be the most practical for pharmacy activities. TRIAL REGISTRATION NUMBER AND THE DATE OF REGISTRATION: ClinicalTrials.gov, NCT04931329. 2021-05-10.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.